UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549  FORM 10-QSB  [X]  QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHNAGE ACT OF 1934  For the quarterly period ended      March 31, 2006  [   ]  TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHNAGE ACT OF 1934  For the transition period from __________________________________to_______________________________________________  Commission File Number: _____________________________________________________________________________________  GLOBAL AGRI-MED TECHNOLOGIES, INC. (Exact name of registrant as specified in its character)  New Jersey22-3720074(State or other jurisdiction of incorporation or organization)(I.R.S. Employer Identification No.) 400 Grove Street, Glen Rock, New Jersey 07452 (201) 445-7399
(Issuer's Telephone Number)  Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2) has been subject to such filing requirements for the past 90 days.      Yes [ X ]    No [   ]  Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerator filer.  See definition of accelerated filer and large accelerated filer in Rule 12b-2 of the Exchange Act (Check one): Large accelerated filer [  ]Accelerated filer [  ]Non-accelerated filer [ X]  Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [   ]     No [ X] The Registrants common stock outstanding as of March 31, 2006 was 8,035,156 shares.  Table of Contents  Page No.  Special Note Regarding Forward Looking Information                                                                                                                              2PART IItem 1.Financial Statements:
Consolidated Balance Sheet as of March 31, 2006 (unaudited) and December 31, 2005 (audited);
Unaudited Consolidated Statements of Operations for the six months ended March 31, 2006 (unaudited) and 2005;
Unaudited Consolidated Statement of Stockholders Equity as of March 31, 2006 and for the year ended December 2005;
Unaudited Consolidated Statement of Cash Flows for the six months ended March 31, 2006 and 2005 (unaudited) and year ended December 2005; and
Notes to Consolidated Financial Statements4
5-6

7

8-9

10-13Item 2.Managements Discussion and Analysis of Financial Condition and Results of Operations13Item 3.Controls and Procedures14PART IIItem 1.Legal Proceedings15Item 2.Unregistered Sales of Equity Securities and use of Proceeds15Item 3.Defaults Upon Senior Securities15Item 4.Submission of Matters to a Vote of Security Holders15Item 5.Other Information15Item 6.Exhibits16SIGNATURE17   2   QUARTERLY REPORT ON FORM 10-QSB FOR GLOBAL AGRI-MED TECHNOLOGIES, INC. SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS To the extent that the information presented in this Quarterly Report on Form 10-QSB for the quarter ended March 31, 2006, discusses financial projections, information or expectations about the products or markets of our company, or otherwise makes statements about the future events, such statements are forward-looking.  We are making these forward-looking statements in reliance on the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.  Although we believe that the expectations reflected in these forward-looking statements are based on reasonable assumptions, there are a number of risks and uncertainties that could cause actual results to differ materially from such forward-looking statements.  These risks and uncertainties are described, among other places in this Quarterly Report, in managements Discussion and Analysis.  Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. In addition, we disclaim any obligations to update any forward-looking statements to reflect events or circumstances after the date of this Quarterly Report.  When considering such forward-looking statements, readers should keep in mind the risks referenced above and the other cautionary statements in this Quarterly Report. PART I. ITEM 1.  FINANCIAL STATEMENTS The condensed financial statements included herein have been prepared by the Company, without audit, pursuant to the rules and regulations of the Securities and Exchange Commission.  Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted pursuant to such rules and regulations, although the Company believes that the disclosures are adequate to make the information presented not misleading. In the opinion of the Company, all adjustments, consisting of only normal recurring adjustments necessary to present fairly the financial position of the Company as of March 31, 2006, and the results of its operations and changes in its financial position from January 1, 2005 through March 31, 2006, have been made.  The results of its operations for such interim period are not necessarily indicative of the results to be expected for the entire year.  These condensed financial statements should be read in conjunction with the financial statements and note thereto included in the Companys annual report on Form 10-KSB for the year ended December 31, 2005.  3    GLOBAL AGRI-MED TECHNOLOGIES, INC.
(a development stage company)
BALANCE SHEETMarch 31,
2006
UnauditedDecember 31,
2005AssetsCurrent assetsCash$100$100Prepaid corporate taxe250250Total current assets350350Other assetsLicense agreement20,00020,000Total other assets20,00020,000Total assets$20,350$20,350Current liabilitiesAccrued liabilities$15,000$13,500Corporate tax payable2,8702,870Officer loan payable36,49136,49154,36152,862Stockholders equityPreferred Stock authorized 10,000,000 shares, no  par value each. At  December 31, 2005, there are no shares outstandingCommon Stock authorized 40,000,000 shares, no  par value each. At March 31, 2006 and December 31, 2005, there are 8,035,156 and 8,035,156  shares outstanding287,442287,442Deficit accumulated during the development stage(321,453)(319,953)Total stockholders equity(34,011)(32,511)Total liabilities and stockholders equity$20,350$20,350============    See accompanying notes to financial statements  4    GLOBAL AGRI-MED TECHNOLOGIES, INC.
(a development stage company)
STATEMENT OF OPERATIONSFor the
year ended
December 31,
2005For the
year ended December 31,
2004For the period from inception (October 28, 1999) to
December 31,
2005Revenue$-0-$-0-$-0-Costs of goods sold-0--0--0-Gross profit-0--0--0-Operations:General and administrative6,64315,36252,511Write down of license agreement value232,500Non cash compensation-shares of common stock issued14,44234,942Depreciation and  amortization-0--0--0-Total expense21,08515,362319,953Net income (loss)$(21,085)$(15,362)$(319,953)Basic and diluted net loss
Per share$(0.00)$(0.00)Basic and diluted weighted
average number of shares
outstanding6,162,0215,628,125    See accompanying notes to financial statements     5    GLOBAL AGRI-MED TECHNOLOGIES, INC.
(a development stage company)
STATEMENT OF OPERATIONSFor the three months ended March 31,
2006
UnauditedFor the three months ended March 31, 2005
UnauditedFor the period from inception (October 28, 1999) to
March 31, 2006
UnauditedRevenue$-0-Costs of goods sold-0-Gross profit-0-Operations:General and administrative$1,500$1,50054,011Write down of license agreement value232,500Non cash compensation-shares of common stock issued34,942Depreciation and  amortization_______________-0-Total expense1,500$1,500321,453Net income (loss)$(1,500)$(1,500)$(321,453)Basic and diluted net loss
Per share$(0.00)$(0.00)Basic and diluted weighted
average number of shares
outstanding8,035,1568,035,156     See accompanying notes to financial statements  6    GLOBAL AGRI-MED TECHNOLOGIES, INC.
(A Development Stage Company)
STATEMENT OF STOCKHOLDERS EQUITY  DatePreferred
stockPreferred
stockCommon StockCommon StockDeficit
accumulated during developmentstageTotalApril 1, 2000-0-$-0-1,190,000$252,500$(43,049)$209,451Net loss_________________________________15,61815,618Balances
December 31, 2000-0-$-0-1,190,000252,500(27,431)225,069Issuance of shares as non-cash  officer compensation1,679,3756,0006,000Net loss_________________________________(6,340)(6,340)Balances
December 31, 2001-0-$-0-2,869,375258,500(33,771)224,729Issuance of shares as non-cash  officer compensation1,379,3756,0006,000Net loss_________________________________(238,740)(238,740)Balances
December 31, 2002-0-$-0-4,248,750264,500(272,511)(8,011)UnauditedIssuance of shares  as non-cash officer compensation1,379,3758,5008,500Loss(10,995)(10,995)Balance 12-31-2003-0-$-0-5,628,125$273,000$(283,506)$(10,506)Net loss(15,362)(15,362)Balance 12-31-2004-0-$-0-5,628,125$273,000$(298,868)$(25,868)UnauditedIssuance of shares as non-cash  officer compensation1,000,0006,0006,000Issuance of shares to Scantek Medical, Inc. pursuant to greement1,407,0318,4428,442Net loss(21,085)(21,085)Balance  12-31-2005-0--0-8,035,156287,442(319,953)(32,511)UnauditedNet loss(1,500)(1,500)Balance March 31, 2006-0--0-8,035,156287,442$(321,453)$(34,011)   See accompanying notes to financial statements  7    GLOBAL AGRI-MED TECHNOLOGIES, INC.
(a development stage company)
STATEMENT OF CASH FLOWSFor the year  ended
December 31,
2005For the year
ended
December 31,
2004For the period from inception (October 28, 1999) to
December 31,
2005CASH FLOWS FROM OPERATING ACTIVITIESNet income (loss)$(21,085)$(15,362)$(319,953)Adjustments to reconcile net loss to cash used in operating activitiesDepreciation- write off of impaired license agreement-0-232,500Non cash expenses - shares of common stock issued as compensation14,44234,942Prepaid corporate taxes(250)(250)Corporate taxes payable7505002,870Accrued expenses6,0006,00013,500TOTAL CASH FLOWS FROM OPERATIONS(143)(8,862)(36,391)CASH FLOWS FROM FINANCING ACTIVITIESOfficer loan payable(200)8,60036,491Sale of stock___________252,500TOTAL CASH FLOWS FROM FINANCING ACTIVITIES(200)8,600288,991CASH FLOWS FROM INVESTING ACTIVITIESPurchase of license agreement(252,500)TOTAL CASH FLOWS FROM INVESTING ACTIVITIES-0-(252,500)NET INCREASE (DECREASE) IN CASH(343)(262)100CASH BALANCE BEGINNING OF PERIOD443705-0-CASH BALANCE END OF PERIOD$100$443$100Non-cash payments$14,442$-0-$20,500Corporate income taxes$-0-$-0-$-0-Interest expense$-0-$-0-$-0-   See accompanying notes to financial statements  8    GLOBAL AGRI-MED TECHNOLOGIES, INC.
(a development stage company)
STATEMENT OF CASH FLOWSFor the three months ended
March 31,
2006
UnauditedFor the three months
ended
March 31,
2005
UnauditedFor the period from inception (October 28, 1999) to
March 31,
2006
UnauditedCASH FLOWS FROM OPERATING ACTIVITIESNet income (loss)$(1,500)$(1,500)$(321,453)Adjustments to reconcile net loss to cash used in operating activitiesDepreciation- write off of impaired license agreement232,500Non cash expenses  shares of common stock issued as compensation34,942Prepaid corporate taxes(250)Corporate taxes payable2,870Accrued expenses1,5001,50015,000TOTAL CASH FLOWS FROM OPERATIONS$ -0-$ -0-(36,391)CASH FLOWS FROM FINANCING ACTIVITIESOfficer loan payable36,491Sale of stock252,500TOTAL CASH FLOWS FROM FINANCING ACTIVITIES288,991CASH FLOWS FROM INVESTING ACTIVITIESPurchase of license agreement(252,500)TOTAL CASH FLOWS FROM INVESTING ACTIVITIES(252,500)NET INCREASE (DECREASE) IN CASH-0--0-100CASH BALANCE BEGINNING OF PERIOD100100-0-CASH BALANCE END OF PERIOD$100$100$100Non-cash payments$-0-$-0-$20,500Corporate income taxes$-0-$-0-$-0-Interest expense$-0-$-0-$-0-     See accompanying notes to financial statements  9   GLOBAL AGRI-MED TECHNOLOGIES, INC. (a development stage company) NOTES TO FINANCIAL STATEMENTS MARCH 31, 2006  NOTE A - BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES  1.   Financial Information-Basis of Presentation  Continuing Operations  During the period required to develop the Companys production facilities and marketing plans, the Company has required and will continue to require additional operating funds.  The Company has suffered net losses and negative operating cash flows since inception.  For the three months ended March 31, 2006; for the year ended December 31, 2005 and for the period from inception( October 28, 1999) to March 31, 2006, the Company had net losses from operations of $1,500; $21,085  and $321,453 respectively, and negative operating cash flows from operations of $-0-; $143.  The Company is in a negative working capital position of $52,511 at March 31, 2006.  The Company must fund the purchase of initial inventory pursuant to contractual relationships with its main supplier Scantek Medical. Funding is also required to organize a marketing infrastructure and production facilities and additional cost required in meeting the compliance requirements of Sarbanes-Oxley.  Funding for Companys operations to date has been provided primarily by officer loans.  For the period from inception (October 28, 1999) to March 31, 2006, the Company is indebted to officers loans aggregating $36,491.  The ultimate success of the Company is dependent upon management's ability to produce and market the Companys products at levels sufficient to generate operating revenues in excess of expenses.  From a financing standpoint, managements focus is on securing sufficient additional capital to build its operating, sales and marketing, and administrative infrastructure to levels needed to generate and support the operations of the Company. Failure to successfully raise this additional capital to fund inventory purchases, secure additional funds for Sarbanes-Oxley compliance, and achieve positive cash flows makes the Companys ability to continue as a going concern uncertain.  While management believes that the Company will be successful in raising the additional capital and achieving profitable operations, no assurances can be given that the Company will be successful in obtaining additional capital or that such financing will be on terms favorable or acceptable to the Company.  The accompanying financial statements have been prepared assuming that the Company will continue as a going concern.  The financial statements do not include any adjustments that might result from the outcome of these uncertainties.  In addition, the financial statements do not include any adjustments relating to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities that might result should the Company be unable to continue as a going concern.  Also, the Company has substantial working capital requirements with meeting compliance requirements with Sarbanes-Oxley.  Management's plans for future operations consist of developing its market share for its medical devices, through product awareness promotional campaigns and development of key manufacturing and distributor relationships for its products and services. The Company does not maintain retail outlets for its products. Rather, the Company intends to sells its products and services through distributors who, in turn, resell the Company's products and services to customers through a variety of distribution channels, including drug stores, wholesalers, the National Health Service and, to a lesser extent, other distribution channels.   The financial statements presented consist of the balance sheet balance sheet as of December 31, 2005 and the related statements of operations and cash flows for the years ended December 31, 2005 and 2004 and for the period from inception (October 28, 1999) to December 31, 2005.  The unaudited financial statements presented consist of the unaudited balance sheet balance sheet as of March 31, 2006 and the related  statements of operations and cash flows for the three months ended March 31, 2006 and 2005 and for the period from inception (October 28, 1999) to march 31, 2006.  10   In order to provide reliable service to its distributors and customers, the Company must continue to develop and maintain favorable relationships with suppliers and members of its distribution channels.  The Company currently maintains a contract with one major supplier, which will not expire until the end of April, 2006, at the earliest. There are no assurances that management will be successful in its marketing plans or that favorable contracts will be negotiated with the major distributors and medical doctors.  2.       Cash Equivalents  Investments having an original maturity of 90 days or less that are readily convertible into cash have been included in, and are a significant portion of, the cash and cash equivalents balances.  3.       Property and Equipment  Property and equipment are stated at cost and are depreciated principally on methods and at rates designed to amortize their costs over their estimated useful lives.  The estimated service lives of property and equipment are principally as follows:  Furniture and fixtures                    5- 7 years Computer equipment                     3- 7 years Computer software                        2- 7 years  Repairs and maintenance are expensed as incurred.  Expenditures that increase the value or productive capacity of assets are capitalized.  When property and equipment are retired, sold, or otherwise disposed of, the asset's carrying amount and related accumulated depreciation are removed from the accounts and any gain or loss is included in operations.  In August 2001, the FASB issued SFAS No. 144, Accounting for the Impairment or Disposal of Long-Lived Assets. This statement addresses financial accounting and reporting for the impairment or disposal of long-lived assets and supersedes FASB No. 121, Accounting for the Impairment of Long-Lived Assets and Long-Lived Assets to Be Disposed Of. The Company does not believe the adoption of these standards will have a material impact on the Company's financial statements.  4.   Revenue and Cost Recognition  The Company recognizes revenue when products are shipped and billed.  5.   Advertising Cost  Advertising costs are expensed as incurred.  Advertising expense fort the for the years ended December 31, 2005 and 2004 and for the period from inception (October 28, 1999) to December 31, 2005, totaled $-0-; $0- and  $-0- for the three months ended March 31, 2006 and 2005 and for the period from inception (October 28, 1999) to March 31, 2006, totaled $-0-; $-0- and $-0-.  6.   Recent Accounting Pronouncements  In December 2004, the Financial Accounting Standards Board (FASB) issued SFAS No. 123 (Revised 2004), Share-Based Payment(SFAS No. 123R). This standard requires expensing of stock options and other share-based payments and supersedes SFAS No. 123, which had allowed companies to choose between expensing stock options or showing pro forma disclosure only. SFAS 123R also supersedes APB Opinion No. 25, Accounting for Stock Issued to Employees, and amends SFAS No. 95, Statement of Cash Flows. This standard will be adopted by us as of January 2006 and will apply to all awards granted, modified, cancelled or repurchased after that date as well as the unvested portion of prior awards. SFAS No. 123R permits public companies to adopt its requirements using one of three methods: the modified prospective method, the modified retrospective method to January 1, 2005, or the modified retrospective method to all prior years for which SFAS No. 123 was effective. We will adopt SFAS No. 123R following the modified prospective method in the first quarter of 2006, as required. As permitted by SFAS No. 123, we currently follow APB Opinion No. 25 which provides for the accounting for share-based payments to employees and directors using the intrinsic value method and, as such, we generally recognized no compensation cost for such stock options. We are currently in the process of assessing the impact that SFAS No. 123R will have on our consolidated income statement in 2006. The historical pro forma income statement disclosure may not be indicative of future results due to the uncertainty of the number of new option grants as well as the assumptions and valuation method used.  11   NOTE B--EARNINGS (LOSS) PER SHARE  Basic net earnings (loss) per common share is computed using the weighted average number of common shares outstanding during the period.  The dilutive effect of potential common shares outstanding is included in diluted net earnings per share. In periods where losses are reported, the weighted average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. Income Taxes The Company provides for the tax effects of transactions reported in the financial statements. The provision if any, consists of taxes currently due plus deferred taxes related primarily to differences  between the basis of assets and liabilities for financial and income tax reporting.  The deferred tax assets and liabilities,  if any  represent  the  future tax  return  consequences  of those differences,  which will  either be taxable  or  deductible  when the assets and liabilities  are recovered or settled.  As of December 31, 2004, the Company had no material current tax liability, deferred tax assets, or liabilities to impact on the Company's  financial  position  because the deferred tax asset related to the  Company's  net  operating  loss  carry  forward  and was fully  offset by a valuation allowance. At December 31, 2005, the Company has net operating loss carry forwards for income tax purposes of $319,953. These carry forward losses are available to offset future taxable income, if any, and expire in the year 2020. The Company's utilization of this carry forward against future taxable income may become subject to an annual limitation due to a cumulative change in ownership of the Company of more than 50 percent. The components of the net deferred tax asset as of December 31, 2005 are as follows: Deferred tax asset:                                 December 31, 2005
Net operating loss carry forward                     $319,953
Valuation allowance                                           (319,953)
                                                                          -------------
Net deferred tax asset                                             $-0- SFAS No. 109 requires that a valuation allowance be provided if it is more likely than not that some portion or all of a deferred tax asset will not be realized.  The Company's ability to realize benefit of its deferred tax asset will depend on the generation of future taxable income.  Because the Company has yet to recognize significant revenue from the sale of its products, the Company believes that a full valuation allowance should be provided. NOTE C - COMMITMENTS AND CONTINGENCIES  During 1997 our then parent company acquired an exclusive license (License Agreement) to manufacture, market and sell a breast abnormality indicator in Chile and Singapore.  All rights to that License Agreement were transferred to the Company in 2000 as part of an arrangement whereby a new business was injected into the parent and the then business of the parent, comprising the License Agreement, was spun off to the then shareholders of the parent.  No additional consideration was paid to the parent for the spun-off asset.  A recent revision, entered into between Scantek Medical and the Company, of that contract dated February 25, 2005, has changed the territories to Chile, and England, Wales and Scotland ("Great Britain", United Kingdom or UK), but requires the Company to make certain payments by April 25, 2005 (extended by    mutual agreement to October 25, 2005). The Distribution Agreement provides that Scantek Medical will receive 20% of the then issued and outstanding common shares of the Company. These shares were issued subsequent to the date of the financial statements. The agreement  further provides   Scantek Medical with the right to convert their interest in the us into 20% of the issued and outstanding common stock of certain subsidiaries that may be formed in the future by the Company. In the event certain payments are not made by the Company as required in the Agreement, then Scantek may choose not to proceed with the new Distribution Agreement, and the Company will be left solely with its original license structure based upon the territory of Chile alone.  Those payments total $650,000 for license fees of which $350,000 was to be paid on or before April 25, 2005, later extended to August 25, 2005, and $300,000 on or before the first anniversary of the Agreement.  As of September 30, 2005, none of these payments have been paid.  If these fees are not paid, and if the agreement is left in effect, the License Fees will be paid through additional royalties to be levied on sales, if any, at the rate of 90% of the gross profit until the License Fees have been paid.  The only additional cost of the Agreement is the $11 per unit price to be paid for the product to Scantek  12   Medical, the sole supplier of the product.  If the license fee is not paid then the License Agreement covering the country of Chile becomes reactivated.  However, management believes that the utilization of the License Agreement poses even more severe problems than the present Agreement.  The write down of the $232,500 in fiscal 2002 reflects the exhaustion of the then issued patents.  Since that time at least one additional patent was obtained (the original patents expired in 2004), but the Companys auditors believed the write down to be required by the applicable generally accepted accounting principles.  Since the License Agreement also covers know how and additional patents the License Agreement will not expire unless revised minimal royalty payments, or regular royalty payments, are not made.  The original  requirement to purchase a turn-key manufacturing plant has been waived.  In fact, Scantek Medical has most recently voiced the opinion that they would like to have additional equipment purchased and installed in their plant for operation by their personnel if demand in the UK develops.  It was agreed between the Company and Scantek Medical that such discussions were premature.  If such a manufacturing line was purchased (and the passage of time has modified what is meant by a manufacturing line) the Company would most likely finance the line by debt and only if the cash flow from sales made such a purchase desirable.  The minimum royalties called for either in the Agreement or the License Agreement would only be paid from sales, if and only if sales develop.  NOTE D - RELATED PARTY TRANSACTIONS  Lease Commitment  The Company occupies office space rent free from Roger Fidler, President at 400 Grove Street, Glen Rock, New Jersey.  Officer Salaries  Roger Fidler, President, is to receive a minimal salary of $500 per month until such time as the Company enters into profitable operations. Officer loan payable The Company is obligated to repay monies advance from Mr. Roger Fidler aggregating $36,491 as of December 31, 2005. These monies are payable on demand and without interest. Issuance of Common Stock As of December 31, 2005, the Company issued 1,407,031 shares of common stock valued at $0.006 per share or $8,442 pursuant to the contractual agreement with Scantek Medical, Inc. and an additional 1,000,000 shares of common stock to Mr. Roger Fidler in lieu of accrued compensation aggregating $6,000 or $0.006 per share.  Development Stage Company  The Company is considered to be a development stage company with little operating history.  The Company is dependent upon the resources of the Company's management and its ability to raise or borrow additional funds to continue to exist. Item 2.    MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS OR PLAN OF OPERATION Plan Of Operation During 1997 the Company's parent acquired an exclusive license (License Agreement) to manufacture, market and sell a breast abnormality indicator in Chile and Singapore.  All rights to that License Agreement were transferred to the Company in 2000 as part of an arrangement whereby a new business was injected into the parent and the then business of the parent, comprising the License Agreement, was spun off to the then shareholders of the parent.  No additional consideration was paid to the parent for the spun-off asset.  A recent revision, entered into between Scantek Medical and the Company, of that contract dated February 25, 2005, has changed the territories to Chile, and England, Wales and Scotland ("Great Britain", United Kingdom or UK)), but requires the Company to make certain payments by April 25, 2005 (extended by mutual agreement to October 25, 2005).  The Distribution Agreement provides that Scantek Medical would receive 20% of the then issued and outstanding common shares of the Registrant  13   (such shares have been issued), and further provides Scantek Medical with the right to convert their interest in the Company into 20% of the issued and outstanding common stock of certain subsidiaries that may be formed in the future by the registrant. In the event certain payments are not made by the Registrant as required in the Agreement, Scantek may choose not to proceed with the new Distribution Agreement, and the Registrant will be left solely with its original license structure based upon the territory of Chile alone.  Those payments total $650,000 for purchase of the distribution rights, in addition to the surrender of the Singapore rights, of which $350,000 was to be paid on or before April 25, 2005, later extended to October 25, 2005, and $300,000 on or before the first anniversary of the Agreement.  If these fees are not paid (and to the date of this filing they have not been paid), and if the agreement is left in effect, the payment for product, currently set at $11 per unit to be paid for the product to Scantek Medical, the sole supplier of the product, will cause 90% of the gross profit to be paid to Scantek Medical until the purchase price is paid in full.  If the license fee is not paid, then the License Agreement covering the country of Chile becomes the surviving agreement.  However, the Company believes that the utilization of the License Agreement poses even more severe problems than the present Agreement.  The write down of the $232,500 in fiscal 2002 reflects the exhaustion of the then issued patents.  Since that time at least one additional patent was obtained (the original patents expired in 2004), but the Companys auditors believed the write down to be required by the applicable generally accepted accounting principles.  Since the License Agreement also covers know how and additional patents the License Agreement will not expire unless revised minimal royalty payments, or regular royalty payments, are not made.  The original requirement to purchase a turn-key manufacturing plant has been waived.  In fact, Scantek Medical has most recently voiced the opinion that they would like to have additional equipment purchased and installed in their plant for operation by their personnel if demand in the UK develops.  It was agreed between the Company and Scantek Medical that such discussions were premature.  If such a manufacturing line was purchased (and the passage of time has modified what is meant by a manufacturing line) the Company would most likely finance the line by debt and only if the cash flow from sales made such a purchase desirable.  The minimum royalties called for either in the Agreement or the License Agreement would only be paid from sales, if and only if sales develop. Over the next twelve months the Company intends to begin a series of steps that hopefully will lead to the utilization of this exclusive distributorship.  Those steps are setting up a wholesaling operation, placing inventory with the wholesaler, providing samples to doctors and clinics so as to encourage introduction of the product and provide for good public relations, additional events to publicize the launch, advertising to create product awareness and later to commence sales through the National Health Service.  The Company has been informed by the manufacturer and counsel in England that the product may be marketed without further regulatory approvals in the UK.  The Company has reached an oral agreement with a medical products wholesaler to carry the initial inventory.  In order to accomplish the remaining goals, the Company will be requiring additional funds to pay for the costs of setting up the marketing systems envisioned. The minor administrative costs for the Company have been and will in all likelihood continue to be borne by the Company's President indefinitely.  The President anticipates being able to meet the cash requirements of the Company until the need for additional funds arises for advertising, samples and public relations related to the launch of the product in the UK.  Through December 31, 2005, the President has loaned the Company $36,491. The Company believes that these additional funds will be needed no later than October, 2005.  If additional funds are not available at that time then the UK launch of the product will be delayed on day by day basis until such financing is available, if ever. The Company is seeking an equity placement in the UK to provide the needed financing.  The Company estimates the minimum cost of the launch to be between $800,000 and $3,000,000 depending upon the geographic scope of the launch.  The Company plans to open a small office in the UK to oversee the launch of the product. The expenses of this office will be made only when, and if, the above mentioned financing is obtained.  If the launch is successful, the Company will then, and only then, hire one or two employees to staff the UK office.  In the meantime, the launch will be supervised by the Companys President. In addition to the risk of not obtaining the additional financing, the Company also faces the risk of lack of product acceptance, the risk attributable to operating in a foreign country and risk of loss during shipment of its product that may not be covered by insurance. Off-Balance Sheet Arrangements We have not entered into any transactions with unconsolidated entities in which we have financial guarantees, subordinated retained interests, derivative instruments or other contingent arrangements that expose us to material continuing risks, contingent liabilities or any other obligations under a variable interest in an unconsolidated entity that provides us with financing, liquidity, market risk or credit risk support.    14   ITEM 3.  CONTROLS AND PROCEDURES The Company maintains disclosure controls and procedures that are designed to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC and that such information is accumulated and communicated to the  Companys management including the Chief Executive Officer/Chief Financial Officer (both offices are occupied by Roger L. Fidler, President of the Company), as appropriate, to allow timely decisions regarding required disclosure.  As required by SEC Rule 13a-15(b), the Company carried out an evaluation, under the supervision and with the participation of the Companys management, including the Chief Executive Officer/Chief Financial Officer concluded that, as of the end of the period covered by this report, the Companys disclosure controls and procedures were effective in ensuring that the information required to be disclosed in reports that the Company files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SECs rules and forms and that such information is accumulated and communicated to the Companys management, including the Chief Executive Officer/Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. There was no change in the Companys internal control over financial reporting during the quarter that ended March 31, 2006 that has materially affected, or is reasonably likely to materially affect, the Companys internal control over financial reporting. PART II  OTHER INFORMATION ITEM 1.  LEGAL PROCEEDINGS From time to time, we may become involved in various lawsuits and legal proceedings which arise in the ordinary course of business. However, litigation is subject to inherent uncertainties, and an adverse result in these or other matters may arise from time to time that may harm our business. We are currently not aware of any such legal proceedings or claims that we believe will have, individually or in the aggregate, a material adverse affect on our business, financial condition or operating results. ITEM 2.  UNREGISTERED SALES OF EQUITY SECURITIES, USE OF PROCEEDS AND PURCHASES OF EQUITY SECURITIES The only sales of unregistered securities of the Registrant during the past three fiscal years were: Common Stock On October 1, 2003 Roger Fidler exchanged 1,379,375 shares for past due salary of $8,500 in reliance upon Section 4(2) of the Securities Act of 1933 and Rule 504 of Regulation D promulgated thereunder in that the sale of restricted securities was made to a single individual who had no intent to immediately re-offer the securities to the public. On October 1, 2005 Roger Fidler exchanged 1,000,000 shares for past due salary of $6,000, in reliance upon Section 4(2) of the Securities Act of 1933 and Rule 504 of Regulation D promulgated thereunder in that the sale of restricted securities was made to a single individual who had no intent to immediately re-offer the securities to the public. On October 1, 2005 Scantek Medical, Inc. was issued 1,407,031 shares valued at $8,442 pursuant to a requirement of the Distribution Agreement and in reliance upon the exemption contained in Section 4(2) of the Securities Act of 1933 and Rule 504 of Regulation D promulgated thereunder in that the restricted securities were sold to a corporation in a isolated transaction with no immediate intent to re-offer the securities to the public. ITEM 3.  DEFAULTS ON SENIOR SECURITIES Not applicable. ITEM 4.  SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS. None.  15   ITEM 5.  OTHER INFORMATION Not applicable. ITEM 6.  EXHIBITS AND REPORTS ON FORM 8-K The Company has not filed any 8-K reports. ITEM 7.  EXHIBITS AND REPORTS ON FORM 8-K The Company has not filed any 8-K reports. Exhibit No. Description (3.1)*Certificate of Incorporation of the Company(3.2)*Bylaws(10)(c)**Fifth Amendment To Exclusive Distribution Agreement Between Scantek Medical, Inc. And Global Agri-Med Technologies, Inc.(10)(d)**Demand Promissory Note(31)Certification of Chief Executive Officer/Chief Financial Officer pursuant to Rule 13a-14(a)/15d-14a(a)(32)Certification of Chief Executive Officer/Chief Financial Officer pursuant to 18 U.S.C. Section 1350 * Previously filed by reference from Form 10SB filed with the Commission on May 13, 2005. **Previously filed by reference from Amendment No. 1 to the Form 10 SB, filed with the Commission on October 31, 2006.  16   SIGNATURES Pursuant to the requirements of Section 13 or 15(d) of the Securities Act of 1934, the Registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized on this 15th day of November, 2006. GLOBAL AGRI-MED TECHNOLOGIES, INC.BY:s/Roger L. FidlerRoger L. FidlerPresident, ChiefFinancial Officerand Director    17